Migalastat | search
Click here to view Migalastat news from 60+ newspapers.
Bookmark or Share- Galafold (migalastat) dosing, indications, interactions, adverse ...Medscape - Fabry disease dosing for Galafold (migalastat), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
- Migalastat Monograph for Professionals - Drugs.comMigalastat is a pharmacological chaperone that reversibly binds to the active site of the alpha-galactosidase A (alpha-Gal A) protein (encoded by the galactosidase alpha gene, GLA), which is deficient in Fabry disease. This binding stabilizes alpha-Gal A allowing its trafficking from the endoplasmic reticulum into the lysosome where it exerts ...
- FDA approves new treatment for a rare genetic disorder, Fabry diseaseThe U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. The drug is indicated for adults with Fabry...
- CIMA ::. FICHA TECNICA GALAFOLD 123 MG CAPSULAS DURASMigalastat no es un sustrato de MDR1 o BCRP, ni tampoco un inhibidor de transportadores de eflujos en humanos BCRP, MDR1 o BSEP. Asimismo, migalastat no es un sustrato de MATE1, MATE2-K, OAT1, OAT3 u OCT2, ni tampoco es un inhibidor de OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1 o de transportadores de absorción en humanos MATE2-K.
- Migalastat Uses, Side Effects & Warnings - Drugs.comWhat is migalastat? Migalastat works by binding to and stabilizing a certain enzyme in the body called alpha-galactosidase A. A deficiency of this enzyme is called Fabry disease. Migalastat is used to treat Fabry disease in adults. Migalastat was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis.
More
